Chai Discovery, an AI molecule-design company, secured a $400 million Series C round that triples its paper value from a prior financing, according to reports. The funding underscores how venture capital continues to back generative modeling systems tied to mainstream pharmaceutical customers. The round positions Chai to expand its AI molecule models used by drugmakers including Lilly, Novartis, and Pfizer—an example of enterprise adoption for computational chemistry. The company’s financing momentum also signals that investors are treating AI-enabled discovery as a primary pipeline engine rather than a supporting tool. For the broader biotech ecosystem, the deal contributes to a pattern: larger venture dollars are clustering around model-building platforms with clear customer pull, while earlier-stage or non-AI tools have faced harder fundraising conditions. Chai’s latest raise raises expectations for model performance, integration into discovery workflows, and measurable reductions in cycle time for lead identification and optimization.